Two Patients Received Human Kidneys After Pig Transplants

Two patients who first received kidneys from genetically engineered pigs have now received organs from human donors. eGenesis, one of a handful of biotech companies pursuing xenografts—transplants between species—announced the result. The two recipients are among its first patients to move from a genetically engineered pig kidney to a human donor organ.

The pressure behind the experiment is a shortage of human organs. Not everyone who needs one can get one, and many people die while waiting. Xenotransplantation offers a possible temporary stopgap: a pig kidney could support a patient before a human organ becomes available.

The obstacle was not only finding a pig kidney that could be transplanted. Scientists also had to consider the immune response. They were unsure whether a temporary pig organ would cause recipients to produce antibodies that could complicate a later human-to-human transplant.

Concretely, the potential benefit is time. A patient unable to receive a human kidney immediately could, in the approach being developed by eGenesis, receive a genetically engineered pig kidney temporarily and later undergo a human transplant. The two cases show that sequence has now occurred for these recipients.

The scale of the result matters. Two patients are covered by the announcement, and STAT describes the early returns as promising while reporting complications. The cases advance the evidence around pig kidneys as a bridge to human donation, but they do not establish how reliably the strategy will work for a wider group of patients.